An east-end Ottawa research firm has acquired another pharmaceutical company working in the cannabinoid space, bolstering both its product pipeline and roster of researchers.
Tetra Bio-Pharma, which develops cannabinoid-based pain relief drugs out of Orléans, announced this week it will acquire Halifax-based Panag Pharma in a cash-and-stock deal worth $12 million. Tetra said in a statement Panag’s patented drug formulations for ocular disease and general neuropathic pain relief will help the local firm expand its commercial operations.
“In completing this acquisition of Panag Pharma we have not only acquired a large portfolio of cannabinoid derived pharmaceutical and natural health products but also a team of scientists that have a substantial amount of expertise in the field,” said Tetra CEO Guy Chamberland in a statement.
(Sponsored)
Advertising or posting a job opportunity is about to get more complicated for many local organizations with 25 or more employees. That’s because of a slew of updates to Ontario’s
New dean of uOttawa’s Faculty of Engineering brings a history of entrepreneurship and innovation
Caroline Cao has been impressed by many aspects of uOttawa’s Faculty of Engineering since being appointed dean in August. But it was after the faculty’s recent Design Day – a
Following the acquisition’s close, which Tetra expects to come later this month following regulatory approvals, Panag will become a wholly-owned but separate subsidiary of the Ottawa-based company. Panag’s shareholders could receive up to $15 million in cash payments from Tetra should the acquired firm reach certain operational milestones in the future.
Tetra Bio-Pharma has raised more than $20 million in funding this past year – including $7.1 million from licensed producer Aphria last November – to advance clinical trials for its drugs aiming to relieve pain for patients in cancer therapy.
